It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...

Affordable, regulated versions of Ozempic, the well-known diabetes and weight-loss shot from Novo Nordisk, are about to hit markets around the world, which could shake up the obesity drug scene. The ...

Albertans may see more and less-expensive varieties of Ozempic on the market soon, after a patent on the drug expired two weeks ago. Ozempic has made headlines in recent years as a popular weight-loss ...

British Columbians could soon have access to cheaper versions of injectable diabetes and obesity drugs. Health Canada is reviewing nine submissions for generic versions of semaglutide, a prescription ...